questionsmedicales.fr
Facteurs biologiques
Pigments biologiques
Pigments biliaires
Bilirubine
Bilirubine : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Bilirubine
Analyse sanguine
Tests de laboratoire
Fonction hépatique
Maladies hépatiques
Obstruction biliaire
Symptômes
5
Hyperbilirubinémie
Jaunisse
Maladies hépatiques
Symptômes
Prévention
5
Ictère néonatal
Prévention
Examens médicaux
Fonction hépatique
Maladies hépatiques
Prévention
Alimentation
Santé du foie
Traitements
5
Hyperbilirubinémie
Traitement
Transfusions sanguines
Anémie hémolytique
Corticostéroïdes
Bilirubine
Photothérapie
Ictère néonatal
Chirurgie
Obstruction biliaire
Complications
5
Complications
Lésions hépatiques
Hyperbilirubinémie
Dommages cérébraux
Obstruction biliaire
Infections
Grossesse
Hyperbilirubinémie
Cirrhose
Insuffisance hépatique
Facteurs de risque
5
Facteurs de risque
Maladies hépatiques
Alcoolisme
Hyperbilirubinémie
Infections virales
Hépatite
Surpoids
Maladies hépatiques
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Bilirubine : Questions médicales les plus fréquentes",
"headline": "Bilirubine : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Bilirubine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-22",
"dateModified": "2026-04-12",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Bilirubine"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Pigments biliaires",
"url": "https://questionsmedicales.fr/mesh/D001654",
"about": {
"@type": "MedicalCondition",
"name": "Pigments biliaires",
"code": {
"@type": "MedicalCode",
"code": "D001654",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.767.193"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Biliverdine",
"alternateName": "Biliverdine",
"url": "https://questionsmedicales.fr/mesh/D001664",
"about": {
"@type": "MedicalCondition",
"name": "Biliverdine",
"code": {
"@type": "MedicalCode",
"code": "D001664",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.767.193.184.200"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Bilirubine",
"alternateName": "Bilirubin",
"code": {
"@type": "MedicalCode",
"code": "D001663",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Claudio Tiribelli",
"url": "https://questionsmedicales.fr/author/Claudio%20Tiribelli",
"affiliation": {
"@type": "Organization",
"name": "The Liver-Brain Unit \"Rita-Moretti\", Fondazione Italiana Fegato-Onlus, Bldg. Q, AREA Science Park, ss14, Km 163.5, Basovizza, 34149 Trieste, Italy."
}
},
{
"@type": "Person",
"name": "Libor Vítek",
"url": "https://questionsmedicales.fr/author/Libor%20V%C3%ADtek",
"affiliation": {
"@type": "Organization",
"name": "4th Department of Internal Medicine and Institute of Medical Biochemistry and Laboratory Diagnostics, General Faculty Hospital and 1st Faculty of Medicine, Charles University, Prague, Czech Republic."
}
},
{
"@type": "Person",
"name": "Silvia Gazzin",
"url": "https://questionsmedicales.fr/author/Silvia%20Gazzin",
"affiliation": {
"@type": "Organization",
"name": "The Liver-Brain Unit \"Rita-Moretti\", Fondazione Italiana Fegato-Onlus, Bldg. Q, AREA Science Park, ss14, Km 163.5, Basovizza, 34149 Trieste, Italy."
}
},
{
"@type": "Person",
"name": "Sri Jayanti",
"url": "https://questionsmedicales.fr/author/Sri%20Jayanti",
"affiliation": {
"@type": "Organization",
"name": "The Liver-Brain Unit \"Rita-Moretti\", Fondazione Italiana Fegato-Onlus, Bldg. Q, AREA Science Park, ss14, Km 163.5, Basovizza, 34149 Trieste, Italy."
}
},
{
"@type": "Person",
"name": "Kosuke Koyano",
"url": "https://questionsmedicales.fr/author/Kosuke%20Koyano",
"affiliation": {
"@type": "Organization",
"name": "Department of Pediatrics, Faculty of Medicine, Kagawa University, Kagawa, Japan."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Demographic dividend-favorable policy environment in two pre-dividend African nations: review of national policies and prospects for policy amendments in Nigeria and Tanzania.",
"datePublished": "2023-06-05",
"url": "https://questionsmedicales.fr/article/37277812",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12889-023-15690-z"
}
},
{
"@type": "ScholarlyArticle",
"name": "Abortion policies at the bedside: a response.",
"datePublished": "2023-11-23",
"url": "https://questionsmedicales.fr/article/37045595",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1136/jme-2023-108948"
}
},
{
"@type": "ScholarlyArticle",
"name": "A mixed method analysis of the Botswana schistosomiasis control policy and plans using the policy triangle framework.",
"datePublished": "2023-09-06",
"url": "https://questionsmedicales.fr/article/37674247",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s41256-023-00321-2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Immigration policy shocks and infant health.",
"datePublished": "2023-10-11",
"url": "https://questionsmedicales.fr/article/37862953",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ehb.2023.101309"
}
},
{
"@type": "ScholarlyArticle",
"name": "The psychology and policy of overcoming economic inequality.",
"datePublished": "2023-08-30",
"url": "https://questionsmedicales.fr/article/37646271",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1017/S0140525X23001103"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Facteurs biologiques",
"item": "https://questionsmedicales.fr/mesh/D001685"
},
{
"@type": "ListItem",
"position": 3,
"name": "Pigments biologiques",
"item": "https://questionsmedicales.fr/mesh/D010860"
},
{
"@type": "ListItem",
"position": 4,
"name": "Pigments biliaires",
"item": "https://questionsmedicales.fr/mesh/D001654"
},
{
"@type": "ListItem",
"position": 5,
"name": "Bilirubine",
"item": "https://questionsmedicales.fr/mesh/D001663"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Bilirubine - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Bilirubine",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-05-25",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Bilirubine",
"description": "Comment mesurer le taux de bilirubine ?\nQuels tests diagnostiques sont utilisés ?\nQu'indique un taux élevé de bilirubine ?\nQuelle est la différence entre bilirubine directe et indirecte ?\nQuels symptômes peuvent nécessiter un test de bilirubine ?",
"url": "https://questionsmedicales.fr/mesh/D001663?mesh_terms=Policy#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Bilirubine",
"description": "Quels sont les symptômes d'une hyperbilirubinémie ?\nLa bilirubine affecte-t-elle la peau ?\nQuels signes indiquent une maladie hépatique ?\nLa bilirubine peut-elle causer des démangeaisons ?\nComment la bilirubine affecte-t-elle l'urine ?",
"url": "https://questionsmedicales.fr/mesh/D001663?mesh_terms=Policy#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Bilirubine",
"description": "Comment prévenir l'ictère néonatal ?\nQuels examens réguliers sont recommandés ?\nComment éviter les maladies hépatiques ?\nLes vaccinations sont-elles importantes ?\nComment une alimentation saine aide-t-elle ?",
"url": "https://questionsmedicales.fr/mesh/D001663?mesh_terms=Policy#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Bilirubine",
"description": "Comment traiter une hyperbilirubinémie ?\nLes transfusions sanguines sont-elles nécessaires ?\nQuels médicaments peuvent réduire la bilirubine ?\nLa photothérapie est-elle efficace ?\nQuand envisager une chirurgie pour la bilirubine ?",
"url": "https://questionsmedicales.fr/mesh/D001663?mesh_terms=Policy#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Bilirubine",
"description": "Quelles complications peuvent survenir avec une bilirubine élevée ?\nL'hyperbilirubinémie peut-elle causer des dommages cérébraux ?\nQuels sont les risques d'une obstruction biliaire ?\nComment l'hyperbilirubinémie affecte-t-elle la grossesse ?\nQuelles sont les conséquences d'une maladie hépatique avancée ?",
"url": "https://questionsmedicales.fr/mesh/D001663?mesh_terms=Policy#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Bilirubine",
"description": "Quels facteurs augmentent le risque d'hyperbilirubinémie ?\nL'alcoolisme est-il un facteur de risque ?\nLes infections virales influencent-elles la bilirubine ?\nLe surpoids est-il un facteur de risque ?\nLes médicaments peuvent-ils affecter la bilirubine ?",
"url": "https://questionsmedicales.fr/mesh/D001663?mesh_terms=Policy#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment mesurer le taux de bilirubine ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le taux de bilirubine est mesuré par une analyse sanguine."
}
},
{
"@type": "Question",
"name": "Quels tests diagnostiques sont utilisés ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent la bilirubine totale et directe, ainsi que des tests hépatiques."
}
},
{
"@type": "Question",
"name": "Qu'indique un taux élevé de bilirubine ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un taux élevé peut indiquer une maladie hépatique, une obstruction biliaire ou une anémie."
}
},
{
"@type": "Question",
"name": "Quelle est la différence entre bilirubine directe et indirecte ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "La bilirubine directe est soluble dans l'eau, tandis que l'indirecte ne l'est pas."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent nécessiter un test de bilirubine ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme jaunisse, fatigue ou douleurs abdominales peuvent nécessiter un test."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une hyperbilirubinémie ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent jaunisse, urine foncée, selles claires et démangeaisons."
}
},
{
"@type": "Question",
"name": "La bilirubine affecte-t-elle la peau ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un excès de bilirubine peut provoquer un jaunissement de la peau et des yeux."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une maladie hépatique ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme la fatigue, l'ictère et des douleurs abdominales peuvent indiquer une maladie hépatique."
}
},
{
"@type": "Question",
"name": "La bilirubine peut-elle causer des démangeaisons ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une accumulation de bilirubine peut provoquer des démangeaisons cutanées."
}
},
{
"@type": "Question",
"name": "Comment la bilirubine affecte-t-elle l'urine ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un taux élevé de bilirubine peut rendre l'urine foncée, semblable à celle du thé."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'ictère néonatal ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'ictère néonatal peut être prévenu par une surveillance attentive des nouveau-nés et une alimentation adéquate."
}
},
{
"@type": "Question",
"name": "Quels examens réguliers sont recommandés ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des examens réguliers de la fonction hépatique sont recommandés pour détecter des anomalies."
}
},
{
"@type": "Question",
"name": "Comment éviter les maladies hépatiques ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter l'alcool, maintenir un poids santé et se faire vacciner contre l'hépatite aide à prévenir les maladies hépatiques."
}
},
{
"@type": "Question",
"name": "Les vaccinations sont-elles importantes ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les vaccinations contre l'hépatite A et B sont cruciales pour prévenir les infections hépatiques."
}
},
{
"@type": "Question",
"name": "Comment une alimentation saine aide-t-elle ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée aide à maintenir la santé du foie et à prévenir l'accumulation de bilirubine."
}
},
{
"@type": "Question",
"name": "Comment traiter une hyperbilirubinémie ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement dépend de la cause sous-jacente, comme des médicaments ou une intervention chirurgicale."
}
},
{
"@type": "Question",
"name": "Les transfusions sanguines sont-elles nécessaires ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, dans certains cas d'anémie hémolytique, des transfusions peuvent être nécessaires."
}
},
{
"@type": "Question",
"name": "Quels médicaments peuvent réduire la bilirubine ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments comme les corticostéroïdes peuvent être utilisés pour traiter certaines conditions."
}
},
{
"@type": "Question",
"name": "La photothérapie est-elle efficace ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la photothérapie est souvent utilisée pour traiter l'ictère néonatal en réduisant la bilirubine."
}
},
{
"@type": "Question",
"name": "Quand envisager une chirurgie pour la bilirubine ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "La chirurgie peut être envisagée en cas d'obstruction biliaire ou de maladies hépatiques graves."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec une bilirubine élevée ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des lésions hépatiques, des troubles neurologiques et des infections."
}
},
{
"@type": "Question",
"name": "L'hyperbilirubinémie peut-elle causer des dommages cérébraux ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une hyperbilirubinémie sévère peut entraîner des dommages cérébraux, surtout chez les nouveau-nés."
}
},
{
"@type": "Question",
"name": "Quels sont les risques d'une obstruction biliaire ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les risques incluent des infections, des douleurs abdominales et des lésions hépatiques."
}
},
{
"@type": "Question",
"name": "Comment l'hyperbilirubinémie affecte-t-elle la grossesse ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut entraîner des complications pour la mère et le fœtus, nécessitant une surveillance étroite."
}
},
{
"@type": "Question",
"name": "Quelles sont les conséquences d'une maladie hépatique avancée ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les conséquences incluent la cirrhose, le cancer du foie et l'insuffisance hépatique."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque d'hyperbilirubinémie ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des maladies hépatiques, des infections et des antécédents familiaux."
}
},
{
"@type": "Question",
"name": "L'alcoolisme est-il un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'alcoolisme peut endommager le foie et augmenter le risque d'hyperbilirubinémie."
}
},
{
"@type": "Question",
"name": "Les infections virales influencent-elles la bilirubine ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des infections comme l'hépatite peuvent augmenter les niveaux de bilirubine."
}
},
{
"@type": "Question",
"name": "Le surpoids est-il un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le surpoids peut contribuer à des maladies hépatiques et à une hyperbilirubinémie."
}
},
{
"@type": "Question",
"name": "Les médicaments peuvent-ils affecter la bilirubine ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments peuvent interférer avec le métabolisme de la bilirubine et augmenter ses niveaux."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 12/04/2026
Contenu vérifié selon les dernières recommandations médicales
7 publications dans cette catégorie
Affiliations :
The Liver-Brain Unit "Rita-Moretti", Fondazione Italiana Fegato-Onlus, Bldg. Q, AREA Science Park, ss14, Km 163.5, Basovizza, 34149 Trieste, Italy.
4 publications dans cette catégorie
Affiliations :
4th Department of Internal Medicine and Institute of Medical Biochemistry and Laboratory Diagnostics, General Faculty Hospital and 1st Faculty of Medicine, Charles University, Prague, Czech Republic.
Publications dans "Bilirubine" :
4 publications dans cette catégorie
Affiliations :
The Liver-Brain Unit "Rita-Moretti", Fondazione Italiana Fegato-Onlus, Bldg. Q, AREA Science Park, ss14, Km 163.5, Basovizza, 34149 Trieste, Italy.
Publications dans "Bilirubine" :
3 publications dans cette catégorie
Affiliations :
The Liver-Brain Unit "Rita-Moretti", Fondazione Italiana Fegato-Onlus, Bldg. Q, AREA Science Park, ss14, Km 163.5, Basovizza, 34149 Trieste, Italy.
Faculty of Medicine, University of Hasanuddin, Makassar 90245, Indonesia.
Molecular Biomedicine Ph.D. Program, Department of Life Sciences, University of Trieste, 34127 Trieste, Italy.
Publications dans "Bilirubine" :
3 publications dans cette catégorie
Affiliations :
Department of Pediatrics, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Publications dans "Bilirubine" :
3 publications dans cette catégorie
Affiliations :
Department of Pediatrics, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Publications dans "Bilirubine" :
3 publications dans cette catégorie
Affiliations :
Department of Pediatrics, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Publications dans "Bilirubine" :
3 publications dans cette catégorie
Affiliations :
Department of Pediatrics, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Publications dans "Bilirubine" :
2 publications dans cette catégorie
Affiliations :
Neonatology Department, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, University Hospital Martin, Martin, Slovakia.
Publications dans "Bilirubine" :
2 publications dans cette catégorie
Affiliations :
Neurology Clinic, Department of Medical, Surgical and Health Sciences, University of Trieste, 34139 Trieste, Italy.
Publications dans "Bilirubine" :
2 publications dans cette catégorie
Affiliations :
Department of Clinical Laboratory, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Publications dans "Bilirubine" :
2 publications dans cette catégorie
Affiliations :
Department of Pediatrics, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Publications dans "Bilirubine" :
2 publications dans cette catégorie
Affiliations :
Department of Clinical Laboratory, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Publications dans "Bilirubine" :
2 publications dans cette catégorie
Affiliations :
Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.
Publications dans "Bilirubine" :
2 publications dans cette catégorie
Affiliations :
Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan.
Publications dans "Bilirubine" :
2 publications dans cette catégorie
Affiliations :
Photonics Center, Skolkovo Institute of Science and Technology, Moscow, Russia.
Publications dans "Bilirubine" :
2 publications dans cette catégorie
Affiliations :
Photonics Center, Skolkovo Institute of Science and Technology, Moscow, Russia.
Publications dans "Bilirubine" :
2 publications dans cette catégorie
Affiliations :
Department of Pediatrics, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Publications dans "Bilirubine" :
2 publications dans cette catégorie
Affiliations :
Italian Liver Fondation, Bldg. Q-AREA Science Park Basovizza, SS14, km. 163,5, 34149 Trieste, Italy.
Publications dans "Bilirubine" :
2 publications dans cette catégorie
Affiliations :
Department of Hepatic Surgery and Liver transplantation Center, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China.
Publications dans "Bilirubine" :
In collaboration with local partners, we reviewed 18 national policy documents across two sub-Saharan African countries identified as pre-dividend nations by the World Bank in 2017: Nigeria and Tanzan...
We conducted policy reviews by focusing on five key sectors of the Gates Institute Demographic Dividend Framework: Family Planning, Maternal and Child Health, Education, Women's Empowerment, and Labor...
Between the two countries, we observed persistent gaps in policies targeting family planning. Although more comprehensive, policies addressing maternal and child health, education, women's empowerment...
Based on these recommendations, as Nigeria, Tanzania, and other pre-dividend nations start experiencing rapid demographic changes, they may consider implementing routine policy reviews to strengthen p...
The present goal of the World Health Organization (WHO) 2021-2030 roadmap for Neglected Tropical Diseases is to eliminate schistosomiasis as a public health problem, and reduce its prevalence of heavy...
The study used a mixed method approaches of an analysis of policy documents and interviews with 12 informants who were purposively selected. Although the informants were recruited from all levels of t...
The study highlights the presence of clear, objectives and targets for the Ngamiland control policy. Another theme was the success in morbidity control, which was realized primarily through cycles of ...
The lack of resources and content in the control of environmental determinants and exclusion of other at-risk groups in the policy, impeded sustained elimination of the disease. There is a need to gui...
This paper evaluates the effect of positive and negative immigration policy shocks on infant health outcomes in the U.S. I examine changes in mean birth weight and the incidence of low birth weight (L...
Recent arguments claim that behavioral science has focused - to its detriment - on the individual over the system when construing behavioral interventions. In this commentary, we argue that tackling e...
To help promote the effective delivery of drug donations, the World Health Organization (WHO) developed the Guidelines for Medicine Donations. The need for revisions is timely given the large-scale in...
A search for medicine donation policies of donors and recipients was conducted in May/June 2022 and repeated in January 2023. Potential donor countries were identified from the high-income countries o...
Our findings suggest that both donors and recipients could further align their policies with the existing Guidelines and both groups should be consulted on any revisions to ensure that their experienc...
Comprehensive sexuality education (CSE) has recently become salient, but adolescent sexual reproductive health and rights (ASRHR) challenges are still a global health problem. Studying policies which ...
We conducted a document review and qualitative interviews with key stakeholders from Non-Governmental Organizations, as well as health and education ministries at the National and all (10) provincial ...
The study highlighted the synergies between policies that create opportunities for implementation of CSE through the policy window for adoption of sexual reproductive health and rights (SRHR) that ope...
While many policies support the implementation of CSE in schools, the existence of policy silences and challenges are among the barriers affecting CSE implementation. Thus, policy reformulation is req...
Despite accumulating evidence of the implications of trade policy for public health, trade and health sectors continue to operate largely in silos. Numerous barriers to advancing health have been iden...
Sixty-five studies met the inclusion criteria and were included in the review. Health issues that received attention on trade policy agendas included: access to medicines, food nutrition and food secu...
The analysis demonstrates that while technical evidence is important, political strategy is necessary for elevating health on trade agendas. The analysis provides lessons that can be explored in the w...
This article introduces the Climate-related Financial Policies Database and provides statistics on its main indicators. The database records many aspects of green financial policymaking for 74 nations...
The database captures various aspects of financial (central banks and financial regulators and supervisors) and non-financial institutions' (ministries, banking associations, governments, and others) ...
International collaborations aim to solve global environmental issues. Academic work and science-policy interfaces are instrumental in this pursuit, although scholars often overlook their significance...